Evolving Landscape of Multiple Myeloma: Current and Emerging Therapies for Frontline and Early Relapse

home / frontline-forum / evolving-landscape-of-multiple-myeloma-current-and-emerging-therapies-for-frontline-and-early

Rafael Fonseca, MD, and Binod Dhakal, MD, analyze recent developments from EHA 2024, including updates on transplant-eligible and ineligible NDMM, the PERSEUS and IsKIA trials, and the impact of CAR T-cell therapy in earlier treatment lines, while offering insights into the evolving treatment landscape and future directions for patient care.

2 KOLs are featured in this series.

EP. 1: Transplant Eligible Multiple Myeloma: Current Standard of Care and Treatment Landscape

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

Medical experts explore the current standard of care and evolving treatment landscape for transplant eligible multiple myeloma, a complex hematological malignancy.

2 KOLs are featured in this series.

EP. 2: Updates from EHA 2024: Review of PERSEUS and IsKIA

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

Multiple myeloma specialists analyze recent findings presented at EHA 2024, offering expert perspectives on the PERSEUS and IsKIA clinical trials and their implications for patient care.

2 KOLs are featured in this series.

EP. 3: Clinical Implications of Updated Data from EHA 2024

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.

2 KOLs are featured in this series.

EP. 4: Updated Data from EHA 2024: Transplant Ineligible NDMM

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

Multiple myeloma experts analyze recent developments in transplant-ineligible newly diagnosed multiple myeloma treatment, focusing on the latest updates presented at EHA 2024 and their potential impact on patient care.

2 KOLs are featured in this series.

EP. 5: Impact of CAR T-cell therapy in Earlier Lines of MM

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.

2 KOLs are featured in this series.

EP. 6: CAR T-cell therapy in MM: Updated Data and the Future

Rafael Fonseca, MD;Binod Dhakal, MD, MS
August 22nd 2024

Experts provide concluding insights on CAR-T cell therapy and offer their perspectives on the evolving treatment landscape for multiple myeloma, highlighting potential future directions and innovations in patient care.